New advances in the treatment of glioblastoma

dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorYi-Ning, Li
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentDrimba, László
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentdeptKenézy Kórház, Központi Aneszteziológiai és Intezív Terápiás Osztályhu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.date.accessioned2020-10-15T08:31:36Z
dc.date.available2020-10-15T08:31:36Z
dc.date.created2019-05-24
dc.description.abstractGlioblastoma (GB) is a refractory malignancy with limited treatment option. Despite current standard of care, GB still has a dismal prognosis. Although GBs are highly malignant and incurable, significant advances in the understanding of the molecular pathology of GBs and associated cell signaling pathways have opened opportunities for new therapies for both newly diagnosed and recurrent GB patients. Gene expression profiling is now being incorporated into a new generation of personalized clinical trials. Furthermore, upcoming trials with immune check-point inhibitors as a new clinical trial paradigm and other immunotherapies are potentially becoming newly advanced treatment modalities for patients in the near future.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent45hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/296748
dc.language.isoenhu_HU
dc.subjectGlioblastomahu_HU
dc.subjecttreatment of glioblastomahu_HU
dc.subject.dspaceDEENK Témalista::Orvostudomány::Farmakológiahu_HU
dc.titleNew advances in the treatment of glioblastomahu_HU
Fájlok